TCT 2018 | PARTNER 2 Valve-in-Valve: Clinical and Hemodynamic Results Maintained in the Long Term

The 1-year follow-up for this study was published last year in JACC, and it showed that transcatheter aortic valve replacement (TAVR) in failed bioprosthetic valves has low rates of complications, boosts significant hemodynamic improvement, and results in relatively low mortality. Now, the 3-year results are presented at TCT 2018.

TCT 2018 | PARTNER 2 Valve-in-Valve: se mantienen los resultados clínicos y hemodinámicos a largo plazoThe study followed 365 patients who underwent valve-in-valve treatment with a Sapien XT failed bioprosthetic valve of less than 21 mm, with ejection fraction less than 20%, and an estimated life expectancy of less than 2 years. The average age of patients was 79 years, the mean Society of Thoracic Surgery (STS) predicted risk of mortality score was 9.1%, and more than 90% of patients had New York Heart Association (NYHA) class III/IV symptoms.

 

Reported mortality at 1 year was 12.1% and at 3 years, 32.7%.

 

The majority of patients were treated with a 23-mm valve, thus generating a 1.2-cm2 mean valve area and a 17.7-mmHg mean gradient after the procedure. These results were maintained throughout 3 years.


Read also: TCT 2018 | TALENT: Ultrathin Struts and Bioresorbable Polymer at the Lowest Possible Cost.


At 3 years, 86% of patients had NYHA class I/II heart symptoms and sustained improvement in quality-of-life scores.

 

Original title: Late Follow-Up After Treatment of Failing Surgical Aortic Bioprosthetic Valves with a Balloon-Expandable Transcatheter Heart Valve.

Presenter: John G. Webb.

 

PARTNER-Valve-in-Valve


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

ACC 2025 | BHF PROTECT-TAVI: Are Cerebral Protection Systems Necessary in TAVI?

TAVI has seen a steady increase in use, though stroke continues to be one of its unwanted complications, mostly ischemic and, less frequently, hemorrhagic. The...

ACC-2025 Congress Second Day Key Studies

BHF PROTECT-TAVI (Kharbanda RK, Kennedy J, Dodd M, et al.)The largest randomized  trial carried out across 33 UK centers between 2020 and 2024, assessing...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

RACE Trial: Effect of Balloon Pulmonary Angioplasty and Riociguat on Right Ventricular Afterload and Function in Chronic Thromboembolic Pulmonary Hypertension

Even though pulmonary endarterectomy is the treatment of choice for chronic thromboembolic pulmonary hypertension (CTEPH), up to 40% of patients are not candidates because...

iFR- vs. FFR-Guided Coronary Revascularization: 5-Year Clinical Outcomes

The assessment of coronary stenosis using coronary physiology has become a key tool in guiding revascularization. The two most widely used techniques are fractional...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...